Five-year data from the FAME 2 study assessing Abbott's (NYSE:ABT) PressureWire, a fractional flow reserve (FFR) diagnostic tool, to better inform stent placement showed improved patient outcomes. The results were presented at EuroPCR in Paris.
Patients who received FFR-guided percutaneous coronary intervention (PCI) plus medical therapy experienced a 13.9% MACE rate (major adverse cardiac event) compared to 27.0% in the group that received medical therapy only. The reduction in MACE was mainly due to reduced urgent revascularization (the need to reestablish blood flow to the heart).
PressureWire measures blood pressure as it flows through a blocked artery which helps the cardiologist determine which vessels would benefit most from stent placement.
Subscribe for full text news in your inbox